Westerterp Marit, Van Eck Miranda, de Haan Willeke, Offerman Erik H, Van Berkel Theo J C, Havekes Louis M, Rensen Patrick C N
The Netherlands Organization for Applied Scientific Research-Quality of Life, Department of Biomedical Research, Gaubius Laboratory, Zernikedreef 9, 2333 CK Leiden, The Netherlands.
Atherosclerosis. 2007 Nov;195(1):e9-16. doi: 10.1016/j.atherosclerosis.2007.01.015. Epub 2007 Feb 23.
Apolipoprotein CI (apoCI) is expressed in the liver and in macrophages, and has several roles in lipid metabolism. Since macrophage apoCI expression might affect macrophage lipid homeostasis and atherosclerotic lesion development locally in the arterial wall, we investigated the effect of both systemic and macrophage apoCI on atherosclerotic lesion development.
To investigate whether physiological expression levels of apoCI affect atherosclerosis development, we first assessed the effect of systemic endogenous apoCI expression on atherosclerosis in apoe-/- apoc1+/+ as compared to apoe-/- apoc1-/- mice at 26 weeks of age. ApoCI expression increased plasma levels of triglycerides (TG) (+70%; P<0.01) and cholesterol (+30%; P<0.05), and increased the atherosclerotic lesion area in the aortic root (+87%; P<0.05). Paradoxically, incubation of apoc1+/+ and apoc1-/- murine peritoneal macrophages with AcLDL (50 microg/mL; 48 h) revealed that macrophage apoCI decreased the accumulation of cellular cholesteryl esters (CE) relatively to free cholesterol (-22%; P<0.05). Accordingly, exogenous human apoCI increased cholesterol efflux from AcLDL-laden wild-type macrophages, and to a similar extent as apoAI and apoE. To evaluate whether atherosclerosis development would be affected by macrophage apoCI expression in vivo, we assessed atherosclerotic lesion development at 16 weeks after transplantation of bone marrow from apoe-/- apoc1-/- or apoe-/- apoc1+/+ mice to apoe-/- apoc1+/+ mice. However, in the situation wherein the liver and adipose tissue still produce apoCI, macrophage apoCI expression did not affect plasma lipid levels or the atherosclerotic lesion area.
Systemic apoCI increases atherosclerosis, probably by inducing hyperlipidemia. Despite decreasing macrophage lipid accumulation in vitro, apoCI production by macrophages locally in the arterial wall does not affect atherosclerosis development in vivo.
载脂蛋白CI(apoCI)在肝脏和巨噬细胞中表达,在脂质代谢中发挥多种作用。由于巨噬细胞apoCI表达可能影响巨噬细胞脂质稳态以及动脉壁局部动脉粥样硬化病变的发展,我们研究了全身和巨噬细胞apoCI对动脉粥样硬化病变发展的影响。
为了研究apoCI的生理表达水平是否影响动脉粥样硬化的发展,我们首先评估了26周龄时,与载脂蛋白E基因敲除(apoe-/-)、载脂蛋白C1基因敲除(apoc1-/-)小鼠相比,载脂蛋白E基因敲除、载脂蛋白C1基因野生型(apoe-/- apoc1+/+)小鼠中全身内源性apoCI表达对动脉粥样硬化的影响。apoCI表达使甘油三酯(TG)血浆水平升高(+70%;P<0.01),胆固醇水平升高(+30%;P<0.05),并使主动脉根部动脉粥样硬化病变面积增加(+87%;P<0.05)。矛盾的是,用乙酰化低密度脂蛋白(AcLDL,50μg/mL;48小时)孵育载脂蛋白C1基因野生型(apoc1+/+)和载脂蛋白C1基因敲除(apoc1-/-)小鼠腹膜巨噬细胞后发现,相对于游离胆固醇,巨噬细胞apoCI使细胞胆固醇酯(CE)积累减少(-22%;P<0.05)。因此,外源性人apoCI增加了载有AcLDL的野生型巨噬细胞的胆固醇流出,且程度与载脂蛋白AI(apoAI)和载脂蛋白E(apoE)相似。为了评估体内巨噬细胞apoCI表达是否会影响动脉粥样硬化的发展,我们评估了将载脂蛋白E基因敲除、载脂蛋白C1基因敲除或载脂蛋白E基因敲除、载脂蛋白C1基因野生型小鼠的骨髓移植到载脂蛋白E基因敲除、载脂蛋白C1基因野生型小鼠16周后的动脉粥样硬化病变发展情况。然而,在肝脏和脂肪组织仍产生apoCI的情况下,巨噬细胞apoCI表达不影响血浆脂质水平或动脉粥样硬化病变面积。
全身apoCI可能通过诱导高脂血症增加动脉粥样硬化。尽管在体外可减少巨噬细胞脂质积累,但动脉壁局部巨噬细胞产生的apoCI在体内不影响动脉粥样硬化的发展。